Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial

World Journal of Urology

Volumn 32, Issue 5, 2014, Pages 1287-1294

  Verhagen, Paul C M S ^a   Wildhagen, Mark F ^a   Verkerk, Annet M ^a   Vjaters, Egils ^b   Pagi, Hembo ^c   Kukk, Leonhard ^c   Bratus, Dejan ^d   Fiala, Richard ^e,f   Bangma, Chris H ^a   Schröder, Fritz H ^a   Mickisch, Gerald H J ^g  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^c North Estonia Regional Hospital   (Estonia)

^d UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^e UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^f NORTHERN HEALTH AND SOCIAL CARE TRUST   (United Kingdom)

^g Centrum für Operative Urologie Bremen   (Germany)

Author keywords

Androgen deprivation therapy (ADT); Cyproterone acetate (CPA); Intermittent ADT; Metastatic prostate cancer

Indexed keywords

EID: 84887770372     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-013-1206-0     Document Type: Article

References (19)

1. Conti PD, Atallah AN, Arruda H et al (2007) Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev CD005009
2. Miller K, Steiner U, Lingnau A et al (2007) Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol 25: 2007 (suppl; abstr 5015)
3. Calais da Silva FE, Bono AV, Whelan P et al (2009) Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European uroncological group. Eur Urol 55:1269–1277
4. Langenhuijsen JF, Badhauser D, Schaaf B et al (2011) Continuous versus intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol 31(5):549–556
5. Hussain M, Tangen CM, Berry DL et al (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314–1325
6. Crook JM, O’Callaghan CJ, Duncan G et al (2012) Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367:895–903
7. de Leval J, Boca P, Yousef E et al (2002) Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 1:163–171
8. Yamanaka H, Ito K, Naito S et al (2005) Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer. Prostate 63:56–64
9. Salonen AJ, Taari K, Ala-Opas M et al (2012) The fin prostate study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol 187:2074–2081
10. Tunn UW, Canepa G, Kochanowsky A, Kienle E (2012) Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy. Prostate Cancer Prostatic Dis 15(3):296–302
11. Sternberg CN, Krainer M, Oh WK et al (2007) The medical management of prostate cancer: a multidisciplinary team approach. BJU Int 99:22–27
12. Tyrrell CJ, Kaisary AV, Iversen P et al (1998) A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33:447–456
13. Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC, O’Boyle PJ (1996) A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 29:47–54
14. Schroder FH, Collette L, de Reijke TM, Whelan P (2000) Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC genitourinary group. European organization for research and treatment of cancer. Br J Cancer 82:283–290
15. Verhagen PC, Wissenburg LD, Wildhagen MF et al (2008) Quality of life effects of intermittent and continuous hormonal therapy by cyproterone acetate (CPA) for metastatic prostate cancer. Eur Urol Suppl 7:206
16. Communication: FDS (2010) Update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labelling regarding increased risk of diabetes and certain cardiovascular diseases. US Food and Drug Administration Web site
17. Nguyen PL, Je Y, Schutz FA et al (2011) Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306:2359–2366
18. Bolla M, de Reijke TM, Van Tienhoven G et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516–2527
19. Verhagen PC, Schroder FH, Collette L, Bangma CH (2010) Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol 58:261–269